Search
TM30339
go.drugbank.com/drugs/DB05085ExperimentalTM30339 works through the same receptor as the natural satiety hormone, Pancreatic Polypeptide (PP), but TM30339 has improved properties compared with PP. … TM30339 thus imitates a natural mechanism, a satiety signal from the gastrointestinal system involved in the regulation of food intake in humans. TM30339 is developed for the treatment of obesity.
Tipiracil
go.drugbank.com/drugs/DB09343ApprovedInvestigationalIt is used in combination with trifluridine, in a ratio of 1:0.5, to form TAS-102. The main function of Tipiracil in TAS-102 is to increase trifluridine bioavailability by inhibiting its catabolism. … [A31255] TAS-102 is indicated for the treatment of metastatic colorectal cancer which has been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, or with an anti-VEGF
Evinacumab
go.drugbank.com/drugs/DB15354ApprovedInvestigational[L31838] In September and December 2023, evinacumab was also approved by Health Canada and EMA, respectively, for the same indication.[L49956,L49966] … hypolipidemia and subsequent reductions in cardiovascular risk, whereas increases in function appear to be associated with cardiovascular risk, and it was these observations that provided a rationale for
Diethylstilbestrol
go.drugbank.com/drugs/DB00255ApprovedWithdrawn(Merck, 11th ed) The FDA withdrew its approval for the use of all oral and parenteral drug products containing 25 milligrams or more of diethylstilbestrol per unit dose.[L43942]
Categories: Hormonal Contraceptives for Systemic Use, Contraceptive Agents, MaleFostamatinib
go.drugbank.com/drugs/DB12010ApprovedInvestigationalIt was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, L52150]. Fostamatinib has also been granted orphan drug status by the FDA [L2644]. … Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP).
Categories: Experimental Unapproved Treatments for COVID-19Velpatasvir
go.drugbank.com/drugs/DB11613ApprovedInvestigationalin combination with sofosbuvir for all six genotypes of Hepatitis C [L852]. … Epclusa is the first combination HCV product indicated for the treatment of all genotypes of Hepatitis C with or without cirrhosis.
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseTamoxifen
go.drugbank.com/drugs/DB00675ApprovedInvestigational[L7799,L7802] Tamoxifen may no longer be the preferred treatment for these types of cancers as patients generally have better survival, side effect profiles, and compliance with [anastrozole]. … [A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.
Bacillus calmette-guerin substrain connaught live antigen
go.drugbank.com/drugs/DB10804ApprovedInvestigationalWithdrawnIt is prepared from the Connaught strain of Bacillus Calmette and Guérin. … Bacillus calmette-guerin substrain connaught live antigen is intravesically administered for the treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder and for the prophylaxis of primary
Taletrectinib
go.drugbank.com/drugs/DB18711ApprovedInvestigational[A274118] Taletrectinib was approved by the US FDA in June 2025 for use in patients with advanced ROS1-positive NSCLC.[L53308,L53523] … [A274158] As part of the second-generation of ROS1 inhibitors, taletrectinib is significantly more potent against ROS1 resistance mutations - for example, the IC50 for taletrectinib against ROS1 exhibiting
Bimekizumab
go.drugbank.com/drugs/DB12917ApprovedInvestigationalBimekizumab is a humanized monoclonal antibody directed towards IL-17, which was approved for use in the EU on August 20, 2021, for the treatment of plaque psoriasis.